Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide + R-DA-EPOCH in untreated MYC-rearranged DLBCL
NCT04432714Phase 2Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Jun 2020
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide in diffuse large B-cell lymphoma (DLBCL), sponsored by Jiangsu Provincial People's Hospital. Primary endpoints: Maximum Tolerated Dose at 21 days, Dose Limiting Toxicity at 21 days and 1 more. Started Jun 2020; status: recruiting.
02
Drugs
lenalidomide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT04432714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04432714.